How to Maximise Your Portfolio and Protect Your Market Share

It is becoming more and more difficult for the pharma industry to conduct business without being confronted with potential infringement to legislation. It is even more difficult considering the recent changes to the pharma legislation and the interactions between IP, competition, regulatory and trade developments.

Hear from the representatives from the top industry experts and their advisers:-
Ark Therapeutics
Schering AG
Sanofi-Aventis UK
Merck Sharp & Dohme Limited
Eli Lilly and Company Limited
Bristows
Taylor Wessing
White & Case
Hogan & Hartson LLP
Cleary Gottlieb
Reed Smith LLP
Wragge & Co LLP
Covington & Burling
Arnold & Porter LLP
AstraZeneca Global Intellectual Property
Novartis Pharma AG
Astellas Pharma Europe Limited
Altana Pharma Limited
Elkington & Fife LLP
Arnold & Porter LLP

They will provide you with practical and comprehensive information and insights from their own experiences on:
> Strategic analysis and critical intelligence on the Pharma legislation, Pediatrics Regulation and Data Exclusivity
> Tactics to address what Pharma companies should be doing to deal with competition from parallel traders
> Winning strategies for optimal SPC protection
> The latest on the impact of the new Bolar provision in the EU
> Secrets of avoiding conflict between competition law and IP law

Master Class on 20th June 07
Plus add value to your attendance by signing up for C5’s Master Class on How You Can Run Your Business without Infringing Competition Rules. This in-depth session, led by Pat Treacy of Bristows, will show you how to master the art of settlement agreements and provide a crucial in-depth rundown of what should be done before the product is placed on the market.

Registration required:

Yes

Free:

No